Psychotropic medication use for behavioral symptoms of dementia

Philip S. Wang, M. Alan Brookhart, Soko Setoguchi Iwata, Amanda R. Patrick, Sebastian Schneeweiss

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Behavioral disturbances associated with dementia are common and burdensome. Although no psychotropic medications are currently approved by the US Food and Drug Administration (FDA) to treat such behavioral symptoms, a variety of drug classes are commonly used for these purposes. Atypical antipsychotic medications may be somewhat effective and are generally considered the pharmacologic treatments of choice; however "black box" warnings have recently been added to their labels by the FDA, warning of significantly increased risks of short-term mortality. Older conventional antipsychotic medications may also be somewhat effective but appear to pose risks that can be at least as great as those of the newer atypical drugs. Although antidepressants, benzodiazepines, mood stabilizers, acetylcholinesterase inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists may be considered, particularly in patients with specific types of symptomatology, even less is known about their effectiveness and safety. Also, although various psychotropic medications used for behavioral disturbances in dementia patients may be somewhat effective, they have been increasingly associated with important safety risks.

Original languageEnglish (US)
Pages (from-to)490-495
Number of pages6
JournalCurrent Neurology and Neuroscience Reports
Volume6
Issue number6
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Behavioral Symptoms
Dementia
United States Food and Drug Administration
Antipsychotic Agents
Drug Labeling
Safety
Cholinesterase Inhibitors
N-Methyl-D-Aspartate Receptors
Benzodiazepines
Pharmaceutical Preparations
Antidepressive Agents
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Wang, Philip S. ; Brookhart, M. Alan ; Setoguchi Iwata, Soko ; Patrick, Amanda R. ; Schneeweiss, Sebastian. / Psychotropic medication use for behavioral symptoms of dementia. In: Current Neurology and Neuroscience Reports. 2006 ; Vol. 6, No. 6. pp. 490-495.
@article{611e007021d9444581bdcd26e4c9d2a8,
title = "Psychotropic medication use for behavioral symptoms of dementia",
abstract = "Behavioral disturbances associated with dementia are common and burdensome. Although no psychotropic medications are currently approved by the US Food and Drug Administration (FDA) to treat such behavioral symptoms, a variety of drug classes are commonly used for these purposes. Atypical antipsychotic medications may be somewhat effective and are generally considered the pharmacologic treatments of choice; however {"}black box{"} warnings have recently been added to their labels by the FDA, warning of significantly increased risks of short-term mortality. Older conventional antipsychotic medications may also be somewhat effective but appear to pose risks that can be at least as great as those of the newer atypical drugs. Although antidepressants, benzodiazepines, mood stabilizers, acetylcholinesterase inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists may be considered, particularly in patients with specific types of symptomatology, even less is known about their effectiveness and safety. Also, although various psychotropic medications used for behavioral disturbances in dementia patients may be somewhat effective, they have been increasingly associated with important safety risks.",
author = "Wang, {Philip S.} and Brookhart, {M. Alan} and {Setoguchi Iwata}, Soko and Patrick, {Amanda R.} and Sebastian Schneeweiss",
year = "2006",
month = "11",
day = "1",
doi = "10.1007/s11910-006-0051-6",
language = "English (US)",
volume = "6",
pages = "490--495",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "6",

}

Psychotropic medication use for behavioral symptoms of dementia. / Wang, Philip S.; Brookhart, M. Alan; Setoguchi Iwata, Soko; Patrick, Amanda R.; Schneeweiss, Sebastian.

In: Current Neurology and Neuroscience Reports, Vol. 6, No. 6, 01.11.2006, p. 490-495.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Psychotropic medication use for behavioral symptoms of dementia

AU - Wang, Philip S.

AU - Brookhart, M. Alan

AU - Setoguchi Iwata, Soko

AU - Patrick, Amanda R.

AU - Schneeweiss, Sebastian

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Behavioral disturbances associated with dementia are common and burdensome. Although no psychotropic medications are currently approved by the US Food and Drug Administration (FDA) to treat such behavioral symptoms, a variety of drug classes are commonly used for these purposes. Atypical antipsychotic medications may be somewhat effective and are generally considered the pharmacologic treatments of choice; however "black box" warnings have recently been added to their labels by the FDA, warning of significantly increased risks of short-term mortality. Older conventional antipsychotic medications may also be somewhat effective but appear to pose risks that can be at least as great as those of the newer atypical drugs. Although antidepressants, benzodiazepines, mood stabilizers, acetylcholinesterase inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists may be considered, particularly in patients with specific types of symptomatology, even less is known about their effectiveness and safety. Also, although various psychotropic medications used for behavioral disturbances in dementia patients may be somewhat effective, they have been increasingly associated with important safety risks.

AB - Behavioral disturbances associated with dementia are common and burdensome. Although no psychotropic medications are currently approved by the US Food and Drug Administration (FDA) to treat such behavioral symptoms, a variety of drug classes are commonly used for these purposes. Atypical antipsychotic medications may be somewhat effective and are generally considered the pharmacologic treatments of choice; however "black box" warnings have recently been added to their labels by the FDA, warning of significantly increased risks of short-term mortality. Older conventional antipsychotic medications may also be somewhat effective but appear to pose risks that can be at least as great as those of the newer atypical drugs. Although antidepressants, benzodiazepines, mood stabilizers, acetylcholinesterase inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists may be considered, particularly in patients with specific types of symptomatology, even less is known about their effectiveness and safety. Also, although various psychotropic medications used for behavioral disturbances in dementia patients may be somewhat effective, they have been increasingly associated with important safety risks.

UR - http://www.scopus.com/inward/record.url?scp=33750984507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750984507&partnerID=8YFLogxK

U2 - 10.1007/s11910-006-0051-6

DO - 10.1007/s11910-006-0051-6

M3 - Review article

C2 - 17074284

AN - SCOPUS:33750984507

VL - 6

SP - 490

EP - 495

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 6

ER -